Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
01 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
11 juin 2024 08h00 HE
|
Biora Therapeutics, Inc.
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
20 mai 2024 08h00 HE
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15 mai 2024 16h05 HE
|
Biora Therapeutics, Inc.
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
07 mai 2024 08h00 HE
|
Biora Therapeutics, Inc.
The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
06 mai 2024 08h00 HE
|
Biora Therapeutics, Inc.
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
30 avr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
08 avr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
04 avr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03 avr. 2024 16h05 HE
|
Biora Therapeutics, Inc.
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...